NCT05897008View on ClinicalTrials.gov

The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity

PHASE1CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

June 27, 2022

Study Completion Date

September 13, 2022

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

CMAB007

for subcutaneous injection only

BIOLOGICAL

Xolair

for subcutaneous injection only

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Taizhou Mabtech Pharmaceutical Co.,Ltd

INDUSTRY